Digest Network Come funziona
Network
/
Società
Im
Non verificato

ImmunityBio, Inc.

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VarieOncologiaSalute

82 comunicati stampa

Guarda tutti i comunicati
21/10/2026
Biotecnologia
Farmaceutica
Oncologia
Salute
Igiene alimentare
Attrezzature medico-sanitarie
Medicina - Varie
Industria
ImmunityBio Announces Database Lock for Registrational Trial of Locally Delivered, Chemotherapy-Free ANKTIVA® Plus BCG in BCG-Naïve Non-Muscle Invasive Bladder Cancer
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
16/10/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
ImmunityBio Reports Phase 3 Data Showing 84% Cystectomy Avoidance at Three Years and Complete Responses Beyond 53 Months with ANKTIVA® Plus BCG in BCG-Unresponsive NMIBC With CIS, With or Without Papillary Tumors
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
14/10/2026
Oncologia
Igiene alimentare
Salute
Medicina - Varie
Farmaceutica
Biotecnologia
FDA Expands ANKTIVA® Approval for BCG-Unresponsive Non-Muscle-Invasive Bladder Cancer to Cover Both Papillary and CIS Disease
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
08/10/2026
Eventi
Web e Social Network
Biotecnologia
Farmaceutica
Oncologia
Salute
Attrezzature medico-sanitarie
HIV, AIDS e malattie autoimmuni
Medicina - Varie
ImmunityBio to Participate in the Piper Sandler Virtual Oncology Symposium
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
10/08/2026
Mercato del lavoro
Biotecnologia
Farmaceutica
Salute
Oncologia
ImmunityBio Appoints Dr. Jim Yong Kim, Former World Bank President and Global Health Leader, as Vice Chairman
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
04/08/2026
Mercato azionario
Biotecnologia
HIV, AIDS e malattie autoimmuni
Salute
Farmaceutica
Oncologia
ImmunityBio Reports Record Q2 2026 Net Product Revenue of $50.7 Million, Up 92% Year-Over-Year; First-Half Revenue Up 121% to $94.8 Million
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
29/07/2026
Oncologia
Salute
Sanità
Scienza
Farmaceutica
Biotecnologia
ImmunityBio Receives United Arab Emirates (UAE) Marketing Authorization for ANKTIVA® Across BCG-Unresponsive Non-Muscle Invasive Bladder Cancer for CIS and Papillary Disease and Metastatic Non-Small Cell Lung Cancer
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
01/06/2026
Eventi
Fiere
Industria
Farmaceutica
Salute
Oncologia
Medicina - Varie
ImmunityBio Presents New Clinical and Comparative Data Across Lung and Bladder Cancer at ASCO 2026
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
22/05/2026
Eventi
Industria
Analisi di mercato
Associazioni/Professionisti
Biotecnologia
Farmaceutica
Oncologia
Salute
HIV, AIDS e malattie autoimmuni
Sanità
ImmunityBio Highlights Patient Survey Data at ISPOR 2026 Showing Majority of UK Adults Living with NMIBC Favor Bladder Preservation
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0
22/05/2026
Farmaceutica
Salute
Oncologia
Medicina - Varie
Eventi
Industria
ImmunityBio Presents Health Economic Analysis at ISPOR 2026 Showing ANKTIVA® Plus BCG Delivers Lower Cost per Sustained Complete Response Versus TAR-200 in BCG-Unresponsive NMIBC CIS
Fonte
ImmunityBio, Inc.
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0